<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34273064</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2592</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical immunology</Title><ISOAbbreviation>J Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study.</ArticleTitle><Pagination><StartPage>1490</StartPage><EndPage>1501</EndPage><MedlinePgn>1490-1501</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10875-021-01083-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">The relationship of host immune response and viral replication with health outcomes in patients with COVID-19 remains to be defined. We aimed to characterize the medium and long-term clinical, virological, and serological outcomes after hospitalization for COVID-19, and to identify predictors of long-COVID.</AbstractText><AbstractText Label="METHODS">Prospective, longitudinal study conducted in COVID-19 patients confirmed by RT-PCR. Serial blood and nasopharyngeal samples (NPS) were obtained for measuring SARS-CoV-2 RNA and S-IgG/N-IgG antibodies during hospital stay, and at 1, 2, and 6&#xa0;months post-discharge. Genome sequencing was performed where appropriate. Patients filled out a COVID-19 symptom questionnaire (CSQ) at 2-month and 6-month visits, and those with highest scores were characterized.</AbstractText><AbstractText Label="RESULTS">Of 146 patients (60% male, median age 64&#xa0;years) followed-up, 20.6% required hospital readmission and 5.5% died. At 2&#xa0;months and 6&#xa0;months, 9.6% and 7.8% patients, respectively, reported moderate/severe persistent symptoms. SARS-CoV-2 RT-PCR was positive in NPS in 11.8% (median Ct&#x2009;=&#x2009;38) and 3% (median Ct&#x2009;=&#x2009;36) patients at 2&#xa0;months and 6&#xa0;months, respectively, but no reinfections were demonstrated. Antibody titers gradually waned, with seroreversion occurring at 6&#xa0;months in 27 (27.6%) patients for N-IgG and in 6 (6%) for S-IgG. Adjusted 2-month predictors of the highest CSQ scores (OR [95%CI]) were lower peak S-IgG (0.80 [0.66-0.94]) and higher WHO severity score (2.57 [1.20-5.86]); 6-month predictors were lower peak S-IgG (0.89 [0.79-0.99]) and female sex (2.41 [1.20-4.82]); no association was found with prolonged viral RNA shedding.</AbstractText><AbstractText Label="CONCLUSIONS">Long-COVID is associated with weak anti-SARS-CoV-2 antibody response, severity of illness, and female gender. Late clinical events and persistent symptoms in the medium and long term occur in a significant proportion of patients hospitalized for COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garc&#xed;a-Abell&#xe1;n</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Internal Medicine and Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padilla</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine and Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, Universidad Miguel Hern&#xe1;ndez de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Gonz&#xe1;lez</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine and Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Jos&#xe9; A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Statistics, Operational Research Center, Universidad Miguel Hern&#xe1;ndez de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agull&#xf3;</LastName><ForeName>Vanesa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Internal Medicine and Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreo</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine and Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Respiratory Medicine, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galiana</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Microbiology Service, Hospital General Universitario de Elche, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez</LastName><ForeName>F&#xe9;lix</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9485-6867</Identifier><AffiliationInfo><Affiliation>Internal Medicine and Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain. gutierrez_fel@gva.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, Universidad Miguel Hern&#xe1;ndez de Elche, Alicante, Spain. gutierrez_fel@gva.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masi&#xe1;</LastName><ForeName>Mar</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9878-2458</Identifier><AffiliationInfo><Affiliation>Internal Medicine and Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante, Spain. marmasiac@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, Universidad Miguel Hern&#xe1;ndez de Elche, Alicante, Spain. marmasiac@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RD16/0025/0038</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>PI16/01740</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>PI18/01861</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>CM19/00160</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>CM20/00066</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>COV20/00005</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>COV20/00156</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Immunol</MedlineTA><NlmUniqueID>8102137</NlmUniqueID><ISSNLinking>0271-9142</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody response</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">viral shedding</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>17</Day><Hour>12</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34273064</ArticleId><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId><ArticleId IdType="pii">10.1007/s10875-021-01083-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199&#x2013;1207. doi: 10.1056/NEJMoa2001316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001316</ArticleId><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28&#x2013;33. doi: 10.1038/s41591-020-01202-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01202-8</ArticleId><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;5. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81:E4&#x2013;E6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020;7:998&#x2013;1002. doi: 10.1093/nsr/nwaa041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa041</ArticleId><ArticleId IdType="pmc">PMC7108005</ArticleId><ArticleId IdType="pubmed">34676125</ArticleId></ArticleIdList></Reference><Reference><Citation>Masi&#xe1; M, Fern&#xe1;ndez-Gonz&#xe1;lez M, Padilla S, Ortega P, Garc&#xed;a JA, Agull&#xf3; V, et al. Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study. EBioMedicine 2020; 60:102999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492814</ArticleId><ArticleId IdType="pubmed">32950003</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Common Investigation Protocol for Investigating Suspected SARS-CoV-2 Reinfection. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/coronavirus/2019-ncov/php/reinfection.html. [Accessed 4 March 2021].</Citation></Reference><Reference><Citation>Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200&#x2013;1204. doi: 10.1038/s41591-020-0965-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0965-6</ArticleId><ArticleId IdType="pubmed">32555424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med. 2020;383:1085&#x2013;1087. doi: 10.1056/NEJMc2025179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2025179</ArticleId><ArticleId IdType="pmc">PMC7397184</ArticleId><ArticleId IdType="pubmed">32706954</ArticleId></ArticleIdList></Reference><Reference><Citation>Duysburgh E, Mortgat L, Barbezange C, Dierick K, Fischer N, Heyndrickx L, et al. Persistence of IgG response to SARS-CoV-2. Lancet Infect Dis. 2021;21:163&#x2013;164. doi: 10.1016/S1473-3099(20)30943-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30943-9</ArticleId><ArticleId IdType="pmc">PMC7833610</ArticleId><ArticleId IdType="pubmed">33341124</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiol. 2020;5:1598&#x2013;1607. doi: 10.1038/s41564-020-00813-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00813-8</ArticleId><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357:1162&#x2013;1163. doi: 10.1056/NEJMc070348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc070348</ArticleId><ArticleId IdType="pubmed">17855683</ArticleId></ArticleIdList></Reference><Reference><Citation>Forthal DN. Functions of Antibodies Microbiol Spectr. 2014;2:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159104</ArticleId><ArticleId IdType="pubmed">25215264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuboi N, Asano K, Lauterbach M, Mayadas TN. Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity. 2008;28:833&#x2013;846. doi: 10.1016/j.immuni.2008.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.04.013</ArticleId><ArticleId IdType="pmc">PMC2577844</ArticleId><ArticleId IdType="pubmed">18538590</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunk S, Sigel S, Metzdorf D, Sharif O, Triantafilou K, Triantafilou M, et al. Internalization and coreceptor expression are critical for TLR2-mediated recognition of lipoteichoic acid in human peripheral blood. J Immunol. 2010;185:3708&#x2013;3717. doi: 10.4049/jimmunol.0901660.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901660</ArticleId><ArticleId IdType="pubmed">20713893</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez N, Renedo M, Alonso S, Crespo MS. Release of arachidonic acid by stimulation of opsonic receptors in human monocytes: the FcgammaR and the complement receptor 3 pathways. J Biol Chem. 2003;278:52179&#x2013;52187. doi: 10.1074/jbc.M310905200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M310905200</ArticleId><ArticleId IdType="pubmed">14532278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov. 2010;9:43&#x2013;56. doi: 10.1038/nrd3011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3011</ArticleId><ArticleId IdType="pubmed">19960015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M, Rodr&#xed;guez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev 2020; 19:102554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198427</ArticleId><ArticleId IdType="pubmed">32380316</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med 13 Jan 2021; NEJMoa2031893. Available at: 10.1056/NEJMoa2031893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821984</ArticleId><ArticleId IdType="pubmed">33523609</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238&#x2013;251. doi: 10.1056/NEJMoa2035002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035002</ArticleId><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184:476&#x2013;488. doi: 10.1016/j.cell.2020.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.015</ArticleId><ArticleId IdType="pmc">PMC7837114</ArticleId><ArticleId IdType="pubmed">33412089</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez LST, Pou C, Lakshmikanth T, Zhang J, Mugabo CH, Wang J, et al. Achieving symptom relief in patients with myalgic encephalomyelitis by targeting the neuro-immune interface and inducing disease tolerance. BioRxiv [Preprint]. February 28, 2020. Available at 10.1101/2020.02.20.958249.</Citation></Reference><Reference><Citation>Blundell S, Ray KK, Buckland M, White PD. Chronic fatigue syndrome and circulating cytokines: a systematic review. Brain Behav Immun. 2015;50:186&#x2013;195. doi: 10.1016/j.bbi.2015.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.07.004</ArticleId><ArticleId IdType="pubmed">26148446</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot X, Ribera A, Gasque P. Chikungunya-induced arthritis in Reunion Island: a long-term observational follow-up study showing frequently persistent joint symptoms, some cases of persistent chikungunya immunoglobulin M positivity, and no anticyclic citrullinated peptide seroconversion after 13 years. J Infect Dis. 2020;222:1740&#x2013;1744. doi: 10.1093/infdis/jiaa261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa261</ArticleId><ArticleId IdType="pubmed">32428203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AM, Wong JG, McAlonan GM, Cheung V, Cheung C, Sham PC, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. Can J Psychiatry. 2007;52:233&#x2013;240. doi: 10.1177/070674370705200405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/070674370705200405</ArticleId><ArticleId IdType="pubmed">17500304</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021;93:1013&#x2013;1022. doi: 10.1002/jmv.26368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall J, Myall K, Lam JL, Mason T, Mukherjee B, West A, et al. Identifying patients at risk of post-discharge complications related to COVID-19 infection. Thorax 2021; Feb 4: thoraxjnl-2020&#x2013;215861.</Citation><ArticleIdList><ArticleId IdType="pubmed">33542090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosey MM, Needham DM. Survivorship after COVID-19 ICU stay. Nat Rev Dis Primers. 2020;6:60. doi: 10.1038/s41572-020-0201-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-020-0201-1</ArticleId><ArticleId IdType="pmc">PMC7362322</ArticleId><ArticleId IdType="pubmed">32669623</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>